share_log

Harmony Biosciences | 8-K: HARMONY BIOSCIENCES REPORTS STRONG FIRST QUARTER FINANCIAL RESULTS AND ACCELERATION OF ITS GROWTH STRATEGY; ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES

Harmony Biosciences | 8-K: HARMONY BIOSCIENCES REPORTS STRONG FIRST QUARTER FINANCIAL RESULTS AND ACCELERATION OF ITS GROWTH STRATEGY; ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES

Harmony Biosciences | 8-K:HARMONY BIOSCIENCES公佈了強勁的第一季度財務業績和增長戰略的加速;推進了PITOLISANT的特許經營權,將收入潛力擴大到2040年以後;加強睡眠/覺醒領導力,實現多元化發展,涉足罕見癲癇
美股SEC公告 ·  04/30 07:50
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息